German conglomerate Bayer (OTCPK:BAYZF) announced Wednesday a global license agreement with Puhe BioPharma to co-develop the ...

Bayer obtains an exclusive worldwide license for MTA-cooperative PRMT5 inhibitor from Suzhou Puhe BioPharma for selective ...

The German conglomerate announced a licensing agreement with Puhe BioPharma for a PRMT5 inhibitor used in a variety of ...

Bayer, Puhe BioPharma ink global license pact to develop, manufacture and commercialize the MTA-cooperative PRMT5 inhibitor: Berlin, Germany Saturday, March 29, 2025, 12:00 Hrs [I ...

MTAP Technologies is a company based in Bengaluru, Karnataka, India, operating in the enterprise tech sector. Founded in 2013 and the company was established by Satvir Singh Kohli, Shiv Kumar ...

Bayer and Suzhou Puhe BioPharma Co. Ltd., a clinical-stage biotechnology company, on Wednesday announced that they have entered into a global license agreement for Puhe BioPharma's oral, small ...

Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel therapies that address emerging targets in oncology, today announced it will present preclinical ...

The metabolic enzyme 5’-deoxy-5'-methylthioadenosine phosphorylase (MTAP) is involved in the methionine salvage pathway, which recycles methionine from methylthioadenosine (MTA). Bayer believes ...